Compare DARE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DARE | AYTU |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | DARE | AYTU |
|---|---|---|
| Price | $1.97 | $2.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $10.00 | $9.33 |
| AVG Volume (30 Days) | 142.4K | ★ 153.3K |
| Earning Date | 11-13-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $63,696,000.00 |
| Revenue This Year | $3,838.11 | N/A |
| Revenue Next Year | $8,711.98 | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $0.95 |
| 52 Week High | $9.19 | $3.07 |
| Indicator | DARE | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | N/A |
| Support Level | $1.88 | N/A |
| Resistance Level | $2.07 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 30.10 | 0.00 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.